FUTURE GENOMICS TECHNOLOGIES BV

Their core work

Future Genomics Technologies BV is a Leiden-based biotech SME that applies genomics and molecular biology tools to two distinct problem areas: diagnosing and controlling parasites in European aquaculture, and engineering microbial cell factories to produce complex plant-derived compounds. In the aquaculture space, they contributed diagnostic kits and immunological tools for fish parasite surveillance. More recently, their work has moved toward metabolic pathway engineering — using yeast as a production platform for therapeutic alkaloids that are otherwise difficult to source. The company's core competence appears to be translating genomic data into applied outputs: diagnostics, bioactivity screening, and microbial production systems.

What they specialise in

How they've shifted over time

In their first H2020 project (2015–2020), Future Genomics Technologies focused entirely on applied aquaculture biology — parasite detection, fish immunology, diagnostic kit development, and integrated pest management for fish farming. By 2019, their second project marked a sharp pivot toward synthetic biology and metabolic engineering, with work on yeast-based production of therapeutic alkaloids through pathway discovery. This trajectory suggests the company is repositioning from diagnostic/surveillance tools toward the higher-value space of engineered biosynthesis — using genomics not just to identify biological threats, but to redesign metabolic pathways for pharmaceutical or nutraceutical production.

They appear to be transitioning from aquaculture diagnostics toward synthetic biology and microbial production of bioactive compounds — a shift that positions them closer to pharmaceutical and industrial biotech markets than food safety.

How they like to work

Future Genomics Technologies has participated in all H2020 projects as a consortium partner, never as coordinator — consistent with a specialist SME that brings specific technical capabilities rather than project management or consortium leadership. Both projects were large RIA consortia, and their 34 unique partners across 13 countries suggest they integrate well into broad European networks without anchoring any particular cluster. There is no evidence of repeat partnerships, which points to an opportunistic collaboration style driven by topic fit rather than long-term alliances.

The company has collaborated with 34 unique partners across 13 countries through just two projects, indicating broad exposure to diverse European consortia rather than a tight repeat-partner network. No single geographic cluster dominates, reflecting the pan-European scope of both RIA projects they joined.

What sets them apart

Future Genomics Technologies occupies an unusual niche for a small SME: they have demonstrated credibility in both applied aquaculture diagnostics and metabolic/synthetic biology, two areas that rarely overlap. Based in Leiden — one of Europe's strongest life science clusters — they likely benefit from proximity to academic spinout networks and biopharma R&D ecosystems. For consortium builders, they represent a rare combination of biological assay expertise and pathway engineering capability, useful in projects that need both analytical and production-side contributions.

Highlights from their portfolio

• MIAMi
  Their largest project by far (EUR 853,750 EC funding), it represents a significant strategic shift into synthetic biology — engineering yeast to produce therapeutic alkaloids at scale, with clear pharmaceutical and industrial relevance.
• ParaFishControl
  A long-running (5-year) pan-European aquaculture project covering diagnostics, immunology, and integrated parasite management — demonstrating the company's ability to contribute applied genomic tools to food security challenges.